Evaluation of Antihypertensive Efficacy and Tolerability of Telmisartan over Losartan on Mild to Moderate Hypertension in a Tertiary Care Hospital

Abstract

Background: Angiotensin II Receptor Blockers (ARBs) are one of the first line drugs for the treatment of hypertension. The objective of the study was to evaluate and compare the efficacy and tolerability between Telmisartan and Losartan in mild to moderate hypertension. Materials & Methods: This prospective analytical study was performed in the Medicine Outpatient Department including Hypertension Clinic of DMCH from January 2022 to December 2022. Total 160 patients with mild to moderate hypertension were divided into two groups; patients in Group A were administered Tab. Telmisartan once daily and patients in group B were administered Tab. Losartan once daily. Results: At baseline and after 6 weeks, there were no significant differences in mean systolic blood pressure (SBP) and mean diastolic blood pressure (DBP) between the two groups. However, at 12 weeks, both mean SBP and mean DBP were significantly lower in Telmisartan group compared to the Losartan group. Serum sodium, serum potassium and serum creatinine levels showed no significant differences throughout the study period. Adverse effects such as dizziness and vomiting were more frequent in Losartan group. Conclusion: Telmisartan demonstrated superior efficacy and better tolerability, making it a preferable option for managing mild-to-moderate hypertension.

Faridpur Med. Coll. J. 2026;21(2):13-19